TY - JOUR
T1 - Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with alzheimer's disease treated with cholinesterase inhibitors
AU - For the Alzheimer’s Disease Neuroimaging Initiative
AU - Alzheimer Precision Medicine Initiative (APMI)
AU - Teipel, Stefan J.
AU - Cavedo, Enrica
AU - Hampel, Harald
AU - Grothe, Michel J.
AU - Aguilar, Lisi Flores
AU - Babiloni, Claudio
AU - Baldacci, Filippo
AU - Benda, Norbert
AU - Black, Keith L.
AU - Bokde, Arun L.W.
AU - Bonuccelli, Ubaldo
AU - Broich, Karl
AU - Bun, René S.
AU - Cacciola, Francesco
AU - Castrillo, Juan
AU - Ceravolo, Roberto
AU - chiesa, Patrizia A.
AU - Colliot, Olivier
AU - Coman, Cristina Maria
AU - Corvol, Jean Christophe
AU - Cuello, Augusto Claudio
AU - Depypere, Herman
AU - Dubois, Bruno
AU - Duggento, Andrea
AU - Durrleman, Stanley
AU - Escott-Price, Valentina
AU - Federoff, Howard
AU - Ferretti, Maria Teresa
AU - Fiandaca, Massimo
AU - Frank, Richard A.
AU - Garaci, Francesco
AU - Genthon, Remy
AU - George, Nathalie
AU - Giorgi, Filippo S.
AU - Graziani, Manuela
AU - Haberkamp, Marion
AU - Habert, Marie Odile
AU - Herholz, Karl
AU - Karran, Eric
AU - Kim, Seung H.
AU - Koronyo, Yosef
AU - Koronyo-Hamaoui, Maya
AU - Lamari, Foudil
AU - Langevin, Todd
AU - Lehéricy, Stéphane
AU - Lista, Simone
AU - Lorenceau, Jean
AU - Mapstone, Mark
AU - Neri, Christian
AU - O'Bryant, Sid E.
N1 - Publisher Copyright:
© 2018 Teipel, Cavedo, Hampel and Grothe.
PY - 2018/8/14
Y1 - 2018/8/14
N2 - Background: Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. Structural MRI markers such as hippocampus or basal forebrain volumes might represent useful instruments for the prediction of cognitive decline. The primary objective was to determine the predictive value of hippocampus and basal forebrain volumes for global and domain specific cognitive decline in AD dementia during cholinergic treatment. Methods: We used MRI and cognitive data from 124 patients with the clinical diagnosis of AD dementia, derived from the ADNI-1 cohort, who were on standard of care cholinesterase inhibitor treatment during a follow-up period between 0.4 and 3.1 years. We used linear mixed effects models with cognitive function as outcome to assess the main effects as well as two-way interactions between baseline volumes and time controlling for age, sex, and total intracranial volume. This model accounts for individual variation in follow-up times. Results: Basal forebrain volume, but not hippocampus volume, was a significant predictor of rates of global cognitive decline. Larger volumes were associated with smaller rates of cognitive decline. Left hippocampus volume had a modest association with rates of episodic memory decline. Baseline performance in global cognition and memory was significantly associated with hippocampus and basal forebrain volumes; in addition, basal forebrain volume was associated with baseline performance in executive function. Conclusions: Our findings indicate that in AD dementia patients, basal forebrain volume may be a useful marker to predict subsequent cognitive decline during cholinergic treatment.
AB - Background: Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. Structural MRI markers such as hippocampus or basal forebrain volumes might represent useful instruments for the prediction of cognitive decline. The primary objective was to determine the predictive value of hippocampus and basal forebrain volumes for global and domain specific cognitive decline in AD dementia during cholinergic treatment. Methods: We used MRI and cognitive data from 124 patients with the clinical diagnosis of AD dementia, derived from the ADNI-1 cohort, who were on standard of care cholinesterase inhibitor treatment during a follow-up period between 0.4 and 3.1 years. We used linear mixed effects models with cognitive function as outcome to assess the main effects as well as two-way interactions between baseline volumes and time controlling for age, sex, and total intracranial volume. This model accounts for individual variation in follow-up times. Results: Basal forebrain volume, but not hippocampus volume, was a significant predictor of rates of global cognitive decline. Larger volumes were associated with smaller rates of cognitive decline. Left hippocampus volume had a modest association with rates of episodic memory decline. Baseline performance in global cognition and memory was significantly associated with hippocampus and basal forebrain volumes; in addition, basal forebrain volume was associated with baseline performance in executive function. Conclusions: Our findings indicate that in AD dementia patients, basal forebrain volume may be a useful marker to predict subsequent cognitive decline during cholinergic treatment.
KW - Basal forebrain
KW - Cholinergic treatment
KW - Executive function
KW - Hippocampus
KW - MRI
KW - Memory
KW - Prediction
UR - http://www.scopus.com/inward/record.url?scp=85051623039&partnerID=8YFLogxK
U2 - 10.3389/fneur.2018.00642
DO - 10.3389/fneur.2018.00642
M3 - Article
AN - SCOPUS:85051623039
SN - 1664-2295
VL - 9
JO - Frontiers in Neurology
JF - Frontiers in Neurology
IS - AUG
M1 - 642
ER -